CompletedNCT00931723
Adding lithium to quetiapine for mania in bipolarity
About this title
Read the official source —Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Montignies-sur-Sambre and 64 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJune 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 356
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Belgium, Bulgaria, Germany, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00931723
- Official title
Show the full official title
An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium Versus Placebo as an Add on to SEROQUEL XR (Quetiapine Fumarate) in Adult Patients With Acute Mania
Get this study by email
Recruitment & locations
CompletedMontignies-sur-Sambre, Belgium · Overpelt, Belgium · Cedex, Belgium
61 more locations
- Dendermonde, Belgium
- Tournai, Belgium
- Burgas, Bulgaria
- Radnevo, Bulgaria
- Cedex, Bulgaria
- Kazanlak, Bulgaria
- Pazardzhik, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Cedex, Germany
- Cologne, Germany
- Berlin, Germany
- Mannheim, Germany
- München, Germany
- Nuremberg, Germany
- Visakhapatnam, India
- Cedex, India
- Ahmedabad, India
- Bangalore, India
- Mangalore, India
- Manipal, India
- Nashik, India
- Jaipur, India
- Kanpur, India
- Cedex, Israel
- Bat Yam, Israel
- Beer Ya'acov, Israel
- Haifa, Israel
- Petah Tikva, Israel
- Tel HaShomer, Israel
- Cedex, Poland
- Bydgoszcz, Poland
- Choroszcz, Poland
- Gorlice, Poland
- Katowice, Poland
- Krakow, Poland
- Lublin, Poland
- Poznan, Poland
- Cedex, Russia
- Arkhangelsk, Russia
- Chita, Russia
- Kazan', Russia
- Moscow, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Voronezh, Russia
- Cedex, South Africa
- Bloemfontein, South Africa
- Vereeniging, South Africa
- Worcester, South Africa
- Cape Town, South Africa
- Johannesburg, South Africa
- Port Elizabeth, South Africa
- Cedex, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Odesa, Ukraine
- Vinnitsia, Ukraine
- Russia
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine fumarate XR, lithium and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolarity type I Pat...
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression